AU2003208228A1 - Formulations and methods of using nitric oxide mimetics in cancer treatment - Google Patents
Formulations and methods of using nitric oxide mimetics in cancer treatmentInfo
- Publication number
- AU2003208228A1 AU2003208228A1 AU2003208228A AU2003208228A AU2003208228A1 AU 2003208228 A1 AU2003208228 A1 AU 2003208228A1 AU 2003208228 A AU2003208228 A AU 2003208228A AU 2003208228 A AU2003208228 A AU 2003208228A AU 2003208228 A1 AU2003208228 A1 AU 2003208228A1
- Authority
- AU
- Australia
- Prior art keywords
- formulations
- methods
- nitric oxide
- cancer treatment
- oxide mimetics
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Abandoned
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/662—Phosphorus acids or esters thereof having P—C bonds, e.g. foscarnet, trichlorfon
- A61K31/663—Compounds having two or more phosphorus acid groups or esters thereof, e.g. clodronic acid, pamidronic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Emergency Medicine (AREA)
- Oncology (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
Applications Claiming Priority (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US36296902P | 2002-03-06 | 2002-03-06 | |
US60/362,969 | 2002-03-06 | ||
US36262002P | 2002-03-07 | 2002-03-07 | |
US60/362,620 | 2002-03-07 | ||
PCT/CA2003/000313 WO2003074082A1 (en) | 2002-03-06 | 2003-03-06 | Formulations and methods of using nitric oxide mimetics in cancer treatment |
Publications (1)
Publication Number | Publication Date |
---|---|
AU2003208228A1 true AU2003208228A1 (en) | 2003-09-16 |
Family
ID=27791719
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
AU2003208228A Abandoned AU2003208228A1 (en) | 2002-03-06 | 2003-03-06 | Formulations and methods of using nitric oxide mimetics in cancer treatment |
Country Status (5)
Country | Link |
---|---|
EP (1) | EP1492567A1 (en) |
JP (1) | JP2005527510A (en) |
AU (1) | AU2003208228A1 (en) |
CA (1) | CA2478145A1 (en) |
WO (1) | WO2003074082A1 (en) |
Families Citing this family (30)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
DE10135815A1 (en) * | 2001-07-23 | 2003-02-06 | Bayer Ag | Use of imidazo-triazinone derivative phosphodiesterase 5 inhibitors e.g. for treatment of cardiac insufficiency, psoriasis, diabetes, cancer, glaucoma, bladder disease, Parkinson's disease or pain |
DK2348114T3 (en) | 2004-04-21 | 2018-09-03 | Alexion Pharma Inc | BONE DELIVERY CONJUGATES AND PROCEDURE TO USE IT FOR TARGETING PROTEINS AGAINST BONE |
US7329495B2 (en) | 2004-06-09 | 2008-02-12 | Board Of Regents, The University Of Texas System | Mutations in KIT confer imatinib resistance in gastrointestinal stromal tumors |
KR20070045187A (en) * | 2004-06-10 | 2007-05-02 | 고쿠리츠다이가쿠호진 도호쿠다이가쿠 | Anticancer effect enhancer |
ES2330934T3 (en) * | 2004-08-19 | 2009-12-17 | Switch Biotech, Llc | USE OF A PDE5 INHIBITOR TO TREAT AND PREVENT HYPOPIGMENTARY DISORDERS. |
AU2005274546B2 (en) * | 2004-08-19 | 2011-02-03 | Switch Biotech, Llc | Use of a PDE5 inhibitor for treating and preventing hypopigmentary disorders |
US20070135380A1 (en) | 2005-08-12 | 2007-06-14 | Radiorx, Inc. | O-nitro compounds, pharmaceutical compositions thereof and uses thereof |
AU2012203798B2 (en) * | 2005-08-12 | 2013-11-07 | Northrop Grumman Systems Corporation | O-nitro compounds, pharmaceutical compositons thereof and uses thereof |
AU2008345034A1 (en) * | 2007-12-27 | 2009-07-09 | Aires Pharmaceuticals, Inc. | Aerosolized nitrite and nitric oxide - donating compounds and uses thereof |
JP5467259B2 (en) * | 2008-03-13 | 2014-04-09 | 国立大学法人 千葉大学 | Cisplatin effect enhancer and anticancer agent kit |
EP2297183A4 (en) * | 2008-05-09 | 2012-07-04 | Univ Duke | Treatment for diseases relying on discovery that thioredoxin mediates nitric oxide release in cells |
US9266939B2 (en) | 2010-12-27 | 2016-02-23 | Alexion Pharmaceuticals, Inc. | Compositions comprising natriuretic peptides and methods of use thereof |
EP2682128B1 (en) * | 2011-02-28 | 2017-11-08 | National Cerebral and Cardiovascular Center | Atrial natriuretic peptide or brain natriuretic peptide for use in preventing metastasis |
JP5842367B2 (en) * | 2011-04-07 | 2016-01-13 | ニプロ株式会社 | Anticancer sensitizer |
US10052366B2 (en) | 2012-05-21 | 2018-08-21 | Alexion Pharmaceuticsl, Inc. | Compositions comprising alkaline phosphatase and/or natriuretic peptide and methods of use thereof |
KR20160143775A (en) | 2014-04-08 | 2016-12-14 | 더 메서디스트 하스피틀 | Inos-inhibitory compositions and their use as breast cancer therapeutics |
WO2016007873A1 (en) | 2014-07-11 | 2016-01-14 | The Regents Of The University Of Michigan | Compositions and methods for treating craniosynostosis |
JP6787894B2 (en) | 2014-12-05 | 2020-11-18 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | Treatment of seizures with recombinant alkaline phosphatase |
JP6868561B2 (en) | 2015-01-28 | 2021-05-12 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | How to treat subjects with alkaline phosphatase deficiency |
MX2018002121A (en) | 2015-08-17 | 2018-06-18 | Alexion Pharma Inc | Manufacturing of alkaline phosphatases. |
WO2017058822A1 (en) | 2015-09-28 | 2017-04-06 | Alexion Pharmaceuticals, Inc. | Identifying effective dosage regimens for tissue non-specific alkaline phosphatase (tnsalp)-enzyme replacement therapy of hypophosphatasia |
EP3368062A4 (en) | 2015-10-30 | 2019-07-03 | Alexion Pharmaceuticals, Inc. | Methods for treating craniosynostosis in a patient |
EP3426286A4 (en) | 2016-03-08 | 2019-12-04 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in children |
WO2017173395A1 (en) | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Methods for treating hypophosphatasia in adolescents and adults |
WO2017173413A1 (en) | 2016-04-01 | 2017-10-05 | Alexion Pharmaceuticals, Inc. | Treating muscle weakness with alkaline phosphatases |
EP3464573A4 (en) | 2016-06-06 | 2020-02-19 | Alexion Pharmaceuticals, Inc. | Metal impact on manufacturing of alkaline phosphatases |
JP7018933B2 (en) | 2016-08-18 | 2022-02-14 | アレクシオン ファーマシューティカルズ, インコーポレイテッド | How to treat bronchomalacia |
CN110719786A (en) | 2017-03-31 | 2020-01-21 | 阿雷克森制药公司 | Methods for treating Hypophosphatasia (HPP) in adults and adolescents |
US11913039B2 (en) | 2018-03-30 | 2024-02-27 | Alexion Pharmaceuticals, Inc. | Method for producing recombinant alkaline phosphatase |
CN114869894A (en) * | 2022-05-10 | 2022-08-09 | 福州大学 | Application of small molecule compound in preparation of urokinase receptor inhibitor drug |
Family Cites Families (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
LV11542B (en) * | 1995-03-30 | 1997-02-20 | Latvijas Organiskas Sintezes Instituts | Substituted 1,3,9,11-tetraoxa-4,5,7,8-tetraazaundecadien-4,7-dioxides-5,7, preparation and use thereof |
AU8398398A (en) * | 1997-07-14 | 1999-02-10 | Brigham And Women's Hospital | Modification of nitric oxide activity to treat fas-induced pathologies |
EP1251840A2 (en) * | 2000-01-26 | 2002-10-30 | Cedars-Sinai Medical Center | Method for using potassium channel activation for delivering a medicant to an abnormal brain region and/or a malignant tumor |
US20010038832A1 (en) * | 2000-04-11 | 2001-11-08 | Benjamin Bonavida | Nitric oxide and analogues thereof effectuate sensitization of neoplasm and immunologically undesired tissues to cytotoxicity |
DE60106905T2 (en) * | 2000-04-26 | 2005-12-01 | Cellegy Pharmaceuticals, Inc., South San Francisco | FORMULATIONS AND METHOD FOR THE USE OF NITROGEN MONEY MIMETICS TO A MALIGNING CELL PHENOTYPE |
-
2003
- 2003-03-06 WO PCT/CA2003/000313 patent/WO2003074082A1/en active Application Filing
- 2003-03-06 JP JP2003572598A patent/JP2005527510A/en active Pending
- 2003-03-06 AU AU2003208228A patent/AU2003208228A1/en not_active Abandoned
- 2003-03-06 EP EP03706181A patent/EP1492567A1/en not_active Withdrawn
- 2003-03-06 CA CA002478145A patent/CA2478145A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
CA2478145A1 (en) | 2003-09-12 |
JP2005527510A (en) | 2005-09-15 |
WO2003074082A1 (en) | 2003-09-12 |
EP1492567A1 (en) | 2005-01-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AU2003208228A1 (en) | Formulations and methods of using nitric oxide mimetics in cancer treatment | |
AU2003293376A1 (en) | Anti-angiogenic compounds and their use in cancer treatment | |
AU2003284242A1 (en) | Methods and compositions for use in treating cancer | |
HK1162948A1 (en) | Hemiasterlin derivatives and uses thereof in the treatment of cancer (hemiasterlin) | |
AU2001293553A1 (en) | Phosphatidylserine-carrying apoptosis-mimicking bodies and the use thereof in medical treatment | |
EP1689348A4 (en) | Oligosaccharide compositions and use thereof in the treatment of infection | |
AU2003265225A1 (en) | Preparations for topical skin use and treatment | |
AU2002341566A1 (en) | Treatment and prevention of mucositis in cancer patients | |
AU2001283285A1 (en) | Antimicrobial composition and methods of use in the treatment of disease | |
EP1560572A4 (en) | Topical parasiticide formulations and methods of treatment | |
AU2002316201A1 (en) | Methods of using colony stimulating factors in the treatment of tissue damage and ischemia | |
GB0615918D0 (en) | Composition and its therapeutic use | |
AU2003298551A1 (en) | Nitric oxide and its biomedical significance | |
AU2003274963A1 (en) | Mda-7 and free radicals in the treatment of cancer | |
AU2003250831A1 (en) | Use of hec1 antagonists in the treatment of proliferative disorders and cancer | |
SG110107A1 (en) | Compound and use in treatment | |
AU2003248763A1 (en) | Methods and contrast agents useful in quantifying nitric oxide | |
AU2003219664A1 (en) | Methods and therapeutic compositions in the treatment of advanced cancer | |
AU2003245858A1 (en) | Uses of ngal-binding substances in the diagnosis and treatment of cancer diseases | |
AU2003209459A1 (en) | Protein-protein interactions in human tumours involving bcmp-7 and bcmp-11 | |
AU2003240446A1 (en) | Use of mob-5 in pain | |
AU2003244437A1 (en) | Quinoxalinones and their use especially in the treatment of cardiovascular diseases | |
EP1643959A4 (en) | Mixtures of calcitonin drug-oligomer conjugates and methods of use in pain treatment | |
AU2002345165A1 (en) | The use of rhein and derivatives thereof in pain treatment | |
AU2003227656A1 (en) | Methods and compositions for treatment of cancer pain |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
MK6 | Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase |